Skip to content

Abstract B052: Understanding latent resistance mechanisms and their phenotypes in pancreatic cancer organoids under KRASG12D inhibition

Sep 2026 · Cancer Research · 0 citations

TL;DR

The rate of acquired resistance to Zoldonrasib was found to be rapid in PCO models and independent of EGF stimulation, and opposing signaling pathway activation in resistant PCOs to Zoldonrasib at 200nM dependent upon EGF stimulation was suggested.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains lethal due to acquired resistance despite the generation of novel targeted therapeutics. Here, we have generated resistant pancreatic cancer organoid (PCO) models to the tri-selective KRASG12D (ON) inhibitor Zoldonrasib to evaluate the rate of acquired resistance and characterize changes at phenotypic resistance. Furthermore, we assessed how dosage of epidermal growth factor (EGF) in media impact resistance mechanisms. PCOs were treated with Zoldonrasib in either standard EGF conditions (50ug/mL) or physiologic EGF conditions (0.5ug/mL) over the course of 96 hours with imaging (Cytation 5) to evaluate their growth rate. PCOs were determined resistant if they held a growth rate above 20% in normalized diameter under continuous treatment. PCO’s were then dose escalated in a log2 fold manner to resistance of 200nM. Resistant PCOs and their parent cultures were collected for protein analysis via western blot (LICOR Odyssey) for alterations in MAP kinase effector signaling. dPCR (QIAcuity) was done to evaluate shifts in copy number variants (CNVs) in key oncogenes post resistance. PCO38 achieved rapid resistance despite the logarithmic escalated doses of Zoldonrasib in 35 days independent of EGF stimulation. Similar, albeit slower (p-value < 0.0001), growth rates were seen in PCO33, with resistance to Zoldonrasib in standard and low EGF conditions in 42 days. Abnormal CNVs of MYC in PCO38 were observed in the parent culture (CNV = 35) and remained unchanged over the course of dose escalation. However, KRAS copy numbers in PCO38 show a limited increase in CNV from a baseline of 3 to 4.5 in standard EGF conditions (p-value = 0.09). Low EGF conditions show non-significant changes in mutant KRAS CNV during dose escalation (p-value > 0.99). Protein analysis suggests opposing signaling pathway activation in resistant PCOs to Zoldonrasib at 200nM dependent upon EGF stimulation. Interestingly, both PCO’s in standard EGF stimulation resulted in activation of the parallel AKT pathway without reactivation of the Ras-ERK node. Physiologic EGF stimulation resulted in no activation of AKT, but instead the re-activation of the Ras-ERK node itself. The rate of acquired resistance to Zoldonrasib was found to be rapid in PCO models and independent of EGF stimulation. dPCR revealed no changes in the abnormal CNVs of MYC, with limited increase in KRASG12D only with standard EGF conditions. Protein analysis suggests that decreased levels of EGF facilitate resistance to Zoldonrasib that is mediated through re-activation of the ERK node. Standard EGF conditions did result in parallel activation of AKT signaling, suggest of model specific off target activation. Ongoing work includes using a druggable CRISPR-Cas9 library screen in latent resistant PCOs to further characterize the diverging mechanisms of resistance dependent upon EGF stimulation. Lauryn E. Flannagan, Michela Cadarso, Audrey G. Sawyer, Md Shahadat Hossan, Jeremy D. Kratz. Understanding latent resistance mechanisms and their phenotypes in pancreatic cancer organoids under KRASG12D inhibition [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B052.

View source

Similar papers

#gene editing Sep 2026

Abstract B067: Dissection of the in vitro response landscape in PDAC under KRAS inhibition reveals co-occurring conserved and adaptive transcription programs

In vitro perturbation is used to decipher the early transcriptional response programs in patient-derived 2D and 3D cell models of PDAC to KRAS inhibition and identify a robust RNA-based signature with potential utility for pharmacodynamic monitoring and the study of adaptive resistance.

H. Schürmann, J. Asche, S. Liffers et al. · 0 citations
Sep 2026

Abstract B087: Impact of RAS inhibition on T cell maturation in the PDAC microenvironment

It is suggested that pharmacologic and genetic KRAS inhibition differentially remodel the intratumoral T cell compartment, whereas both induce similar T cell changes within the liver premetastatic niche.

Lauren Gerbereux, Rashmi Kumar, E. Lasse-Opsahl et al. · 0 citations
Sep 2026

Abstract B061: Epigenetic EZH2 dependency in KRAS inhibitor-resistant PDAC cells

The findings uncover an epigenetically-driven resistance mechanism in which EZH2 promotes NE differentiation and provides a bypass signaling under KRAS inhibition, and may represent a promising therapeutic strategy to overcome KRAS inhibitor resistance and improve the clinical outcome for PDAC patients.

G. Outeiro-Pinho, Aref Hosseini, Maciej Garczyk et al. · 0 citations
Sep 2026

Abstract B127: Synthetic Lethality Through Combined BET and CDK9 Inhibition in MYC-Amplified Pancreatic Ductal Adenocarcinoma

It is demonstrated that dual BET and CDK9 inhibition promotes transcriptional pausing and suppresses key regulators in transcriptionally driven cancers, as well as demonstrating on-target transcriptional inhibition.

Paulina N. Esguerra, Michela Cadarso, Sasha Livingwell et al. · 0 citations
Sep 2026

Abstract A036: Elucidating MYC allelic imbalance and therapeutic response in pancreatic ductal adenocarcinoma via patient-derived organoids

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with an unmet need for novel precision based therapies. While KRAS canonically drives tumor progression, MYC amplification has emerged as a critical downstream resistance mechanism. Efforts have been made to elucidate the role of MYC amplification in PDAC...

Audrey G. Sawyer, Lauryn E. Flannagan, Paulina N. Esguerra et al. · 0 citations
Sep 2026

Abstract B043: Targeting dual CDK9 and KRASG12D selective inhibition as a novel combination therapy in pancreatic ductal adenocarcinoma

A patient-derived cancer organoid (PCO) model that is MYC-amplified is examined to assess the activity of combining CDK9 inhibition (SLS009) with tricomplex RAS (ON inhibitors) studying both RMC-6236 and RMC-9805 and significantly augments the induction of apoptosis and necrosis compared to single agent activity.

Michela Cadarso, Paulina N. Esguerra, Lauryn E. Flannagan et al. · 0 citations

Related blog posts

Google DeepMind Blog Sep 30, 2026

Introducing SynthID Bio

Proof of concept for watermarking AI-generated proteins while preserving biological function.

MIT News · Artificial Intelligence Aug 27, 2026

Looking beyond natural sequences

A new machine-learning framework aims to improve the success rate of computational protein design while moving away from results that reproduce sequences found in nature.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.